Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

From neuroprogression to neuroprotection: implications for clinical care.

Berk M, Conus P, Kapczinski F, Andreazza AC, Yücel M, Wood SJ, Pantelis C, Malhi GS, Dodd S, Bechdolf A, Amminger GP, Hickie IB, McGorry PD.

Med J Aust. 2010 Aug 16;193(4 Suppl):S36-40.

PMID:
20712560
2.

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.

Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS.

Neurosci Biobehav Rev. 2011 Jan;35(3):804-17. doi: 10.1016/j.neubiorev.2010.10.001. Epub 2010 Oct 8. Review.

PMID:
20934453
3.

Evidence and implications for early intervention in bipolar disorder.

Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C, Yucel M, Pantelis C, Murphy B, Vieta E, Dodd S, McGorry PD.

J Ment Health. 2010 Apr;19(2):113-26. doi: 10.3109/09638230903469111. Review.

PMID:
20433320
4.

Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?

Lagace DC, Eisch AJ.

Psychiatr Clin North Am. 2005 Jun;28(2):399-414. Review.

PMID:
15826739
5.

Early intervention in bipolar disorders: opportunities and pitfalls.

Berk M, Hallam K, Lucas N, Hasty M, McNeil CA, Conus P, Kader L, McGorry PD.

Med J Aust. 2007 Oct 1;187(7 Suppl):S11-4. Review.

PMID:
17908017
6.

Putative neuroprotective agents in neuropsychiatric disorders.

Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:135-45. doi: 10.1016/j.pnpbp.2012.11.007. Epub 2012 Nov 23. Review.

PMID:
23178231
7.

Mediators of allostasis and systemic toxicity in bipolar disorder.

Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F.

Physiol Behav. 2012 Apr 12;106(1):46-50. doi: 10.1016/j.physbeh.2011.10.029. Epub 2011 Nov 3. Review.

PMID:
22079584
8.

Valproate and neuroprotective effects for bipolar disorder.

Atmaca M.

Int Rev Psychiatry. 2009;21(4):410-3. doi: 10.1080/09540260902962206. Review.

PMID:
20374154
9.

Cognitive impairment in bipolar disorder: an overview.

Manove E, Levy B.

Postgrad Med. 2010 Jul;122(4):7-16. doi: 10.3810/pgm.2010.07.2170. Review.

PMID:
20675966
10.

Staging and neuroprogression in bipolar disorder: a systematic review of the literature.

Gama CS, Kunz M, Magalhães PV, Kapczinski F.

Rev Bras Psiquiatr. 2013 Mar;35(1):70-4. Review.

11.

Neuroprotective therapies.

Simon DK, Standaert DG.

Med Clin North Am. 1999 Mar;83(2):509-23, viii. Review.

PMID:
10093591
12.

Magnetic resonance findings in bipolar disorder.

Brambilla P, Glahn DC, Balestrieri M, Soares JC.

Psychiatr Clin North Am. 2005 Jun;28(2):443-67. Review.

PMID:
15826742
13.

Identifying and treating cognitive impairment in bipolar disorder.

Goldberg JF, Chengappa KN.

Bipolar Disord. 2009 Jun;11 Suppl 2:123-37. doi: 10.1111/j.1399-5618.2009.00716.x. Review.

PMID:
19538691
14.

Hypothalamic-pituitary-adrenal axis and bipolar disorder.

Daban C, Vieta E, Mackin P, Young AH.

Psychiatr Clin North Am. 2005 Jun;28(2):469-80. Review.

PMID:
15826743
15.

Staging and neuroprogression in bipolar disorder.

Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargél AA, Kunz M, Kapczinski F.

Curr Psychiatry Rep. 2012 Dec;14(6):667-75. doi: 10.1007/s11920-012-0319-2. Review.

PMID:
23090632
16.

Cognition in bipolar disorder.

Osuji IJ, Cullum CM.

Psychiatr Clin North Am. 2005 Jun;28(2):427-41. Review.

PMID:
15826741
17.

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.

Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK.

Mol Psychiatry. 2004 Aug;9(8):756-76. Review.

PMID:
15136795
18.

Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder.

Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, Magalhães PV, Kapczinski F.

Expert Rev Neurother. 2013 Jul;13(7):827-42. doi: 10.1586/14737175.2013.811981. Review.

PMID:
23898853
19.

The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.

Moylan S, Maes M, Wray NR, Berk M.

Mol Psychiatry. 2013 May;18(5):595-606. doi: 10.1038/mp.2012.33. Epub 2012 Apr 24. Review.

PMID:
22525486
20.

Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives.

Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, Andreazza AC, Frey BN, Kapczinski F.

J Affect Disord. 2009 Apr;114(1-3):1-13. doi: 10.1016/j.jad.2008.08.011. Epub 2008 Sep 26. Review.

PMID:
18819715

Supplemental Content

Support Center